With Yervoy Approved in Europe, Bristol Activates Reimbursement Talks
This article was originally published in The Pink Sheet Daily
BMS hopes that compelling survival data and unmet need will accelerate European patients' access to its novel advanced melanoma drug Yervoy.
You may also be interested in...
Bristol-Myers Squibb is using a "new customer model" that takes a holistic approach to supporting Yervoy (ipilimumab), CEO Lamberto Andreotti told analysts on the company's first-quarter earnings call on April 28.
Bristol-Myers Squibb's immunotherapy Yervoy (ipilimumab) will enter the market positioned for wide use, with a broad label for its approval for metastatic melanoma and positive Phase III results for front-line patients.
The British drug costs regulator turns down Roche's Tarceva, Pierre Fabre's Javlor and PharmaMar's Yondelis for use in the NHS in certain indications.